GC Aesthetics introduces the GCA Comfort Plus Warranty – the new lifetime warranty

GC Aesthetics Ltd, one of the world’s leading producers of silicone implants has announced a brand new lifetime warranty on all GC Aesthetics’ breast implants1.

With more than 3 million implants sold in the last 10 years2 and long-term market experience and expertise, GC Aesthetics (GCA) is introducing a brand new lifetime warranty which provides additional coverage to show their commitment to patients and their wellbeing.

The previous GCA Comfort Guarantee provided free of charge implant replacements in the event of rupture or capsular contracture (Baker grade III or IV) post implantation surgery. This coverage will now be enhanced with the new GCA Comfort Plus warranty

The new warranty continues to provide free of charge implant replacements in the event of rupture or capsular contracture (Baker grade III or IV) post implantation surgery, and also now provides free, automatic and retrospective cover for BIA-ALCL (Breast Implant Associated-Anaplastic Large Cell Lymphoma) when clinically diagnosed by surgeons or other medically qualified professionals for products implanted since 1st of January 2009.

In addition, in the case of a confirmed BIA-ALCL the new warranty could provide reimbursement of up to $3,000 towards the cost of necessary medical scan(s) and the cost of necessary surgery to remove the GC Aesthetics breast implant(s) and replace them with a more suitable GCA solution.

GC Aesthetics will replace breast implants with any model, size, or style from the significant range of GCA breast implants currently featured in their catalogue.

This warranty improvement is a significant additional benefit and provides additional coverage for patients with GC Aesthetics’ (Nagor or Eurosilicone) silicone gel-filled breast implants. Furthermore, the upgraded warranty is also key for plastic surgeons when deciding on the choice of implant to use based on a recent Global Market Research study3

During the last 10 years, there have been no cases of BIA-ALCL with GC Aesthetics’ smooth breast implants and a rate of less than 0.0007% with GC Aesthetics’ textured breast implants.4

The risk of developing BIA-ALCL in patients with breast implants is extremely rare, GCA recognises the need for patients and surgeons to have peace of mind and feel safe with their chosen products, which have been carefully developed by experts and are backed up by long-term clinical data5 

Manuela Schneider-Höfferer, PhD Chief Marketing Officer (CMO), said:

“Our employees are proud about the quality of our implants, our strong clinical data and long-term relationships with our customers and patients. Upgrading our warranty to a Comfort Plus Warranty is our way to continue to be a real for life partner for all our customers. Safety always comes first and providing confidence to our patients is essential”.

Regarding the importance of the GCA Comfort Plus warranty for both patients and physicians, who will both find reassurance from this update, Manuela commented: 

“For more than 40 years, GC Aesthetics through its Nagor and Eurosilicone brands has been a reliable partner in the Women Healthcare Aesthetic surgery domain. Every day we work closely with recognized surgeons and understand that the dialogue with their patients regarding BIA-ALCL is not always easy. The Comfort Plus Warranty will help both surgeons and patients to facilitate this communication by providing even more security, reliability and giving patients peace of mind.”

For more information regarding the GCA Comfort Plus warranty, both existing patients, physicians and those considering silicone implants can visit the GC Aesthetics website for the latest information and updates. 

 

Notes to Editors

 

About GC Aesthetics 

GC Aesthetics is an established global medical technology company that develops, manufactures in-house and markets a comprehensive range of proprietary aesthetic products that empower patients to feel confident and secure in their personal journey. Throughout 40 years of commercial presence, GCA has been dedicated to advancing the science of medical aesthetics and delivering high-quality silicone breast implants under its premium Nagor and Eurosilicone brands, primarily for breast augmentation and breast reconstructive surgery. More than 3 million women and men across 70 countries have trusted GCA products, which are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness. The company’s vertically integrated strategy enables exceptional clinical, operational and commercial performance, which allows GCA to provide competitively differentiated products to physicians and patients. Through a culture of continuous innovation and dedication to customer-responsiveness, GCA has established itself as a leading provider of medical aesthetics solutions and the partner-of-choice for patients seeking to improve their lives.

Contact Details

Holly Barry / Digital PR Strategist / Holly@theevergreenagency.co.uk
GC Aesthetics Marketing / marketing@gcaesthetics.com 

 

Footnotes:

COVID-19 – Information for our Global Community

Dear partners,

The health and wellbeing of our staff, customers and partners is a priority for all of us at GC Aesthetics.

We recognise that this is an exceptional time of uncertainty and rapid change for everyone in our global community. Within GC Aesthetics our COVID-19 response team is continuously monitoring the latest news and guidance issued by national and international agencies.

To ensure adherence to the latest recommendations and safeguard the health of our employees and stakeholders we have taken the following measures:

  • Our staff who have the ability to work from home will do so until further notice.
  • We have cancelled ALL international and non-essential travel for our staff.
  • Within our operational facilities we have implemented additional strict hygiene control measures.
  • We have robust Human Resources policies relating to notification and self-isolation.
  • We are adapting our operating capacity and distribution schedule to meet current demand and comply with local regulations.

GC Aesthetics is committed to safeguarding the health of our global community. We ask for your understanding during this time should any of the above measures impact or inconvenience you.

This unique situation requires a co-ordinated response and we will continue to work with our partners and global community to navigate this period together.

If you have any specific questions please contact your local GC Aesthetics representative.

Yours sincerely,

Carlos Reis Pinto

CEO

GC Aesthetics supports the International Society of Aesthetic Plastic Surgery as Gold Sponsor

Dublin, Ireland – 4 September 2019 – GC Aesthetics (GCA), a global medical technology company with over 40 years of experience, is pleased to announce that it has become a Gold Sponsor of the International Society of Aesthetic Plastic Surgery (ISAPS).

GCA is committed to supporting surgeons in their professional development, whether through continuous training and networking activities at ISAPS events and workshops, or through our own GCA Academy, a digital training platform that hosts a range of live surgeries, webinars, and lectures sharing best practice.

“GC Aesthetics is proud to become a gold sponsor at ISAPS. As a global market leader with over 40 years of experience in medical aesthetics for women, we believe passionately in encouraging innovation and education that ensure the best outcomes for patients and surgeons. Working closely with ISAPS allows to combine our expertise in providing best-in class training to plastic surgeons around the world,”

said Carlos Reis Pinto, Chief Executive Officer of GC Aesthetics. Dr. Dirk Richter, President of ISAPS, added:

“I’m welcoming GC Aesthetics as selected ISAPS Global Gold Sponsor and looking forward to a fruitful cooperation.”

ISAPS is the world’s leading professional body for board-certified aesthetic plastic surgeons. Founded in 1970, ISAPS membership includes the world’s best known and respected reconstructive and aesthetic plastic surgeons in over 100 countries on every continent, reflecting the true international mission of the organization.

GC Aesthetics at London Breast Meeting 2019 (4-7 September/venue: Royal college of Physicians): booth #6

About GC Aesthetics

GC Aesthetics (GCA) is an established global medical technology company that develops, manufactures in-house and markets a comprehensive range of proprietary aesthetic products that empower patients to feel confident and secure in their personal journey. Throughout 40 years of commercial presence, GCA has been dedicated to advancing the science of medical aesthetics and delivering high-quality products under its premium Nagor and Eurosilicone brands, primarily for breast augmentation and breast reconstructive surgery. More than 3 million women and men across 70 countries have trusted GCA products, which are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness. The Company’s vertically integrated strategy enables exceptional clinical, operational and commercial performance, which allows GCA to provide competitively differentiated products to physicians and patients. Through a culture of continuous innovation and dedication to customer-responsiveness, GCA has established itself as a leading provider of medical aesthetics solutions and the partner-of-choice for patients seeking to improve their lives.

Contact

info@gcaesthetics.com

BIA-ALCL GC Aesthetics Communication update

The Australian Therapeutic Good Administration (TGA) has released a public statement of the preliminary outcomes from its review of textured implants on July 11, 2019. The notice proposes certain actions the TGA may take in relation to textured implants used in Australia. GC Aesthetics is surprised about this public statement, given the overall very low occurrence rate of BIA-ALCL compared to other medical conditions. It is important to notice that no final decision has been taken at this stage. GCA, as well as other responsible manufacturers, are transparently communicating with TGA and stand by our robust data and clinically proven safety

GC Aesthetics’ implant safety has been proven through a number of large scale, long term prospective clinical studies in over 1000 patients, including the only two large scale prospective European study of breast implants with 10-year patient follow up. With over 3 million implants sold over the last 10 years across 70 countries GCA’s safety record is quite clear:

  •   The global rate of BIA-ALCL associated with GCA textured implants is <0.0007%
  •   The global rate of BIA-ALCL associated with GCA smooth implants is 0%

GCA is at the forefront of the industry with a prominent and permanent focus on patient safety. We will continue to closely monitor the incidence of BIA- ALCL and participate in collaborative global research. We also remain committed to transparency with our doctors and patients about this and any other safety concerns.

Yours sincerely,

Carlos Reis Pinto CEO

GC Aesthetics to Launch Two New Products in Brazil and Europe

Dublin, Ireland – June 20, 2019 – GC Aesthetics, Inc. (GCA), a privately-held medical technology company providing aesthetic solutions for global healthcare markets, announced today that the Company will be launching two new products.

The first product, Eve 4.0, will be launched at the 39 th Paulista Plastic Surgery Journey Conference that is taking place from June 19-22, 2019 in Sao Paulo, Brazil. Eve 4.0 is a proprietary Digital Consultation Solution (DCS) allowing augmented reality visualization that offers a unique experience for patients who are considering either breast augmentation or reconstruction. The Eve 4.0 uses the latest software technologies available to the medical technology industry to do a breast simulation, allowing physicians and their patients to see how they will look after surgery, thus reducing patient uncertainty and making breast surgery an easier decision between physician and patient. GCA can be found at Booth 46 at the 39th Paulista Plastic Surgery Journey Conference at the Hyatt Hotel convention center in Sao Paulo. On June 20 at 10:30 local time, a live demonstration of Eve 4.0 is planned to take place at the booth and will also be livestreamed on GCA’s social media channels. Following the conference, Eve 4.0 will be rolled out in Europe and Brazil.

In parallel with the launch of Eve 4.0, GCA will also be launching the Noa recovery compression solutions in Europe. Noa is a FDA- approved, medical-grade compression solution that incorporates a patented 3D compression system. The healing process after procedures that cause trauma to the body has been shown to last on average 12 weeks, during which the body requires proper support to heal. The GCA Noa product family are easy to get on, are designed for comfort and healing immediately following surgery and have been shown to help reduce swelling and pain, to control moisture in order to prevent infection, and to allow the patient to move easily and to also sleep comfortably. The initial roll out of the Noa product will be in Germany, the United Kingdom, Spain, and Italy and progressively will be extended into additional geographies where GCA has a presence.

“As a global market leader with over 30 years of experience in medical aesthetics, GCA is passionate about moving the industry forward through innovation and extraordinary customer experiences,”

commented Carlos Reis Pinto, Chief Executive Officer at GC Aesthetics.

“These products represent the evolution of GCA to expanding beyond being only an implant manufacturer and to becoming a true partner to our surgeon and their patients providing solutions throughout their journey.”

About the 39th Paulista Plastic Surgery Journey Conference

The 39th Jornada Paulista will take place from June 19-22, 2019 in Sao Paulo, Brazil. It is the second most important event in Brazil organized by the Brazilian Society of Plastic Surgery of São Paulo. The Scientific Program is developed by well-recognized physicians in plastic surgery. It is estimated that over 1,200 plastic surgeons will attend the conference this year.
For more information: link here

About GC Aesthetics

GC Aesthetics (GCA) is an established global medical technology company that develops, manufactures in-house and markets a comprehensive range of proprietary aesthetic products that empower patients to feel safe and confident on their personal journey. Through 30 years of commercial presence, GCA has been dedicated to advancing the science of medical aesthetics and delivering high-quality products under its premium Nagor and Eurosilicone brands, primarily for breast augmentation and breast reconstructive surgery. More than 3 million women and men across 70 countries have trusted GCA products, which are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness. The Company’s vertically-integrated strategy enables exceptional clinical, operational and commercial performance, which allows GCA to provide competitively differentiated products to physicians and patients. Through a culture of continuous innovation and dedication to customer-responsiveness, GCA has established itself as a leading provider of medical aesthetics solutions and the partner-of-choice for patients seeking to improve their lives.

Contact 

info@gcaesthetics.com

10 Year Data Shows Long-Term Safety and Efficacy of GC Aesthetics Implants

GC Aesthetics (GCA) announced today that data from a European clinical study of over 500 women implanted with the GC Aesthetics’ Eurosilicone breast implants was published online on the April 27, 2019 in Aesthetic Surgery Journal Open Forum. The study, titled “Ten-Year Safety Data for Eurosilicone’s Round and Anatomical Silicone Gel Breast Implants,” looked at Eurosilicone’s Cristalline Paragel gel-filled mammary implants when used in breast augmentation and reconstructive surgery and is the largest long-term European study conducted to date on breast implants.

“The results of this long-term study are among the best in the industry,” said Professor Franck Duteille, MD, Plastic Reconstructive and Aesthetic Surgery at University Hospital in Nantes and Principle Investigator of the study. “The endpoints were achieved and can be observed through the low complication rates for capsular contracture and rupture, as well as through the low number of patients who experienced local complications such as haematoma, seroma and infection.”

Study participants received GC Aesthetics’ Eurosilicone textured mammary implants for primary (423 women) and revision (103 women) surgeries in 17 centers throughout France. Complications were recorded at 3 months and annually thereafter for 10 years.

The 10-year outcomes show Kaplan-Meier risk estimates for patients in the primary augmentation cohort as:

  • 4.9% rupture
  • 13.8% capsular contracture (Baker Grade III & IV)

“The results obtained from this large scale European clinical study of our textured breast implants confirms GC Aesthetics’ 30-year commitment to continually delivering safe, innovative technologies to our customers, demonstrated through independent clinical research and daily support provided by our dedicated employees,” commented Carlos Reis Pinto, Chief Executive Officer of GC Aesthetics. “In addition to this exciting data, we are awaiting approval to start another long-term European clinical study on our smooth breast implants. We are working collaboratively with partners across the industry as we remain focused on patient safety and care.”

About GC Aesthetics

GC Aesthetics (GCA) is an established global medical technology company that develops, manufactures in-house and markets a comprehensive range of proprietary aesthetic products that empower patients to feel safe and confident on their personal journey. Through 30 years of commercial presence, GCA has been dedicated to advancing the science of medical aesthetics and delivering high-quality products under its premium Nagor and Eurosilicone brands, primarily for breast augmentation and breast reconstructive surgery. More than 3 million women and men across 70 countries have trusted GCA products, which are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness. The Company’s vertically-integrated strategy enables exceptional clinical, operational and commercial performance, which allows GCA to provide competitively differentiated products to physicians and patients. Through a culture of continuous innovation and dedication to customer-responsiveness, GCA has established itself as a leading provider of medical aesthetics solutions and the partner-of-choice for patients seeking to improve their lives.

Contacts

GC Aesthetics

info@gcaesthetics.com

 

GC Aesthetics (GCA) announced today that data from a European clinical study of over 500 women implanted with the GC Aesthetics’ Eurosilicone breast implants was published online on the April 27, 2019 in Aesthetic Surgery Journal Open Forum. The study, titled “Ten-Year Safety Data for Eurosilicone’s Round and Anatomical Silicone Gel Breast Implants,” looked at Eurosilicone’s Cristalline Paragel gel-filled mammary implants when used in breast augmentation and reconstructive surgery and is the largest long-term European study conducted to date on breast implants.

“The results of this long-term study are among the best in the industry,” said Professor Franck Duteille, MD, Plastic Reconstructive and Aesthetic Surgery at University Hospital in Nantes and Principle Investigator of the study. “The endpoints were achieved and can be observed through the low complication rates for capsular contracture and rupture, as well as through the low number of patients who experienced local complications such as haematoma, seroma and infection.”

Study participants received GC Aesthetics’ Eurosilicone textured mammary implants for primary (423 women) and revision (103 women) surgeries in 17 centers throughout France. Complications were recorded at 3 months and annually thereafter for 10 years.

The 10-year outcomes show Kaplan-Meier risk estimates for patients in the primary augmentation cohort as:

  • 4.9% rupture
  • 13.8% capsular contracture (Baker Grade III & IV)

“The results obtained from this large scale European clinical study of our textured breast implants confirms GC Aesthetics’ 30-year commitment to continually delivering safe, innovative technologies to our customers, demonstrated through independent clinical research and daily support provided by our dedicated employees,” commented Carlos Reis Pinto, Chief Executive Officer of GC Aesthetics. “In addition to this exciting data, we are awaiting approval to start another long-term European clinical study on our smooth breast implants. We are working collaboratively with partners across the industry as we remain focused on patient safety and care.”

About GC Aesthetics

GC Aesthetics (GCA) is an established global medical technology company that develops, manufactures in-house and markets a comprehensive range of proprietary aesthetic products that empower patients to feel safe and confident on their personal journey. Through 30 years of commercial presence, GCA has been dedicated to advancing the science of medical aesthetics and delivering high-quality products under its premium Nagor and Eurosilicone brands, primarily for breast augmentation and breast reconstructive surgery. More than 3 million women and men across 70 countries have trusted GCA products, which are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness. The Company’s vertically-integrated strategy enables exceptional clinical, operational and commercial performance, which allows GCA to provide competitively differentiated products to physicians and patients. Through a culture of continuous innovation and dedication to customer-responsiveness, GCA has established itself as a leading provider of medical aesthetics solutions and the partner-of-choice for patients seeking to improve their lives.

 

A Note from GC Aesthetics To Address BIA-ALCL Concerns

Following recent concerns that have been raised about a possible connection between textured breast implants and the rare condition known as anaplastic large cell lymphoma (BIA-ALCL), the French government agency responsible for medicines and health products (ANSM) announced today that it will, until further notice, ban the sale in France of what they classify as macro-textured breast implants manufactured by several companies. While respectful of the French regulators’ position, and consistent with a long-standing focus on patient safety, GC Aesthetics (“GCA”) will immediately suspend the sale in France of the affected products.  GCA is also committed to working with ANSM to demonstrate the long-term safety record of the affected products.

GCA has for almost 40 years offered the broadest range of breast implants in the industry, including smooth implants with the latest innovative gel technology, as well as a large offering of  textured products that are not impacted by this recent ANSM decision, across both our Nagor and Eurosilicone brands. These products, which together serve a significant portion of GCA customers in France, will continue to be sold in France.  Given this broad offering and market share of unaffected GCA products in France, the company is confident that the impact of the ANSM action on GCA and our customers should not be significant.

GCA is able to support our safety claims with the only two large scale prospective European studies of both textured and smooth breast implants, with 10-years of patient follow up.  Furthermore, with over 3 million implants sold over the last 10 years across 70 countries, the rate of BIA-ALCL incidence for GCA textured implants is less than 0.0007%, and it is 0% for GCA smooth implants over the same period.

The proven and long-standing safety record of GCA’s products has enabled the company to provide a platform for continuous investment into our robust research and development activities. These activities have enabled GCA to ensure that our products are safe and highly effective in achieving the needs of our doctors and patients.

With patient safety as our top priority, we will continue to closely monitor the incidence of BIA-ALCL and participate in collaborative global research.  GCA is committed to continuing to be well positioned at the forefront of the industry with a permanent focus on patient safety.

GC Aesthetics Announces Progress in U.S. Regulatory Strategy and Key Hires to Support Growth

GC Aesthetics (“GCA”), a medical technology company providing healthcare aesthetic solutions for global healthcare markets, announced today several recent positive developments for the Company, demonstrating continued progress on its U.S. and international growth strategy.

Initiating Clinical Study to Support FDA Approval.

On December 31, 2018, GCA signed a letter of intent with ICON Clinical Research Limited (ICON), a global Clinical Medical Research Organization, whereby ICON will provide clinical and regulatory services to support a FDA Pre-Market Approval for GC Aesthetics breast implants for both aesthetic and reconstructive indications within the United States. The agreement is linked to a multi-year GC Aesthetics Silicone Gel Breast Implant Pivotal Study. GCA expects to submit an Investigational Device Exemption application to the FDA in the second half of 2019.

Appointment of U.S. Leadership

In conjunction with the Company’s engagement with ICON, GCA also recently announced the appointment of Ron Cosmas as U.S. Project Manager. In this position, Mr. Cosmas will establish a local presence for GCA in the United States, and will be responsible for cultivating brand awareness, instituting a key opinion leader network and spearheading the FDA approval process for GCA breast implant products in the United States. Mr. Cosmas has over 20 years of experience working with aesthetic medical device companies in the U.S. with key players such as McGhan Medical, Allergan, Sientra, Keller Medical and OBP Medical. He has significant experience with, and expertise in, the U.S. FDA regulatory approval process.

Appointment to the Board of Directors. 

GCA is also excited to announce the appointment of Mariano García-Valiño to the Company’s Board of Directors. Mr. García-Valiño has been active at the intersection of healthcare, strategy and entrepreneurship for over 25 years. Most recently, Mr.  García-Valiño was CEO of GBT (B3:GBIO33), a biopharmaceutical company with presence in the 10 largest Latin American markets that he helped to build and then took public in 2017. Prior to GBT, Mr. García-Valiño led the Latin-American business for Bausch+Lomb, and had various senior executive roles with Pfizer, Eli Lilly, McKinsey, Advent International and Warburg Pincus in Europe, the United States and Latin-America. Mr. Garcia-Valiño holds an engineering degree from Universidad de Buenos Aires and an MBA from the Harvard Business School.  He is based in Montevideo, Uruguay.

“We are thrilled about the recent developments and progress at GC Aesthetics.”

Said Carlos Reis Pinto, Chief Executive Officer of GC Aesthetics.

“We are committed to advancing our products for women seeking safe, empowering breast augmentation or reconstruction solutions. The combination of adding aesthetic industry veteran Ron Cosmas to our team and our partnership with global clinical research leader ICON will help us in achieving our strategy of bringing our new generation of breast implant technology to the United States. I also welcome Mariano García-Valiño to our board. Mariano brings invaluable experience in the healthcare aesthetics industry, and his insights in scaling operations in fast-growing international aesthetics markets will be essential as we expand our market leadership and build the new standard in helping women around the world be their best-self.”

About GC Aesthetics

GC Aesthetics (“GCA”) is an established global medical technology company that develops, manufactures in-house and markets a comprehensive range of proprietary aesthetic products that empower patients to feel safe and confident on their personal journey. Through 30 years of commercial presence, GCA has been dedicated to advancing the science of medical aesthetics and delivering high-quality products under its premium Nagor and Eurosilicone brands, primarily for breast augmentation and breast reconstructive surgery. More than 2.5 million women and men across 70 countries have trusted GCA products, which are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness. The Company’s vertically-integrated strategy enables exceptional clinical, operational and commercial performance, which allows GCA to provide competitively differentiated products to physicians and patients. Through a culture of continuous innovation and dedication to customer-responsiveness, GCA has established itself as a leading provider of medical aesthetics solutions and the partner-of-choice for patients seeking to improve their lives.

 

Contact

info@gcaesthetics.com

GC Aesthetics Raises $97 Million in Financing

GC Aesthetics (“GCA”), a medical technology company providing aesthetic solutions for global healthcare markets, announced today that the company has raised $97 million of new capital. The financing comprises a combination of debt, provided by Hayfin Capital Management (“Hayfin”), and an equity investment from GCA’s existing investors, including Montreux Equity Partners, Barry’s Tea and Oyster Capital Partners. Proceeds from the financing will be used to refinance GCA’s outstanding debt, to fund advancement of an IDE study to support FDA approval of the Company’s breast implant products in the United States, and to fund additional product innovation and growth initiatives at GCA.

“We are very pleased with the strong support from our existing investors and are delighted to have Hayfin, who is a preeminent lender in the healthcare space, as our new lending partner,”

commented Carlos Reis Pinto, Chief Executive Officer of GCA.

“This financing, along with our continued solid financial performance, validates the strength and potential of our global, vertically-integrated healthcare aesthetics implant business. Additionally, the refinancing of our existing debt provides GCA with financial flexibility to pursue strategic growth initiatives, including the possibility of entering the U.S. market with our competitively differentiated products.”

Howard Rowe, Managing Director and Head of Healthcare at Hayfin, stated,

“Hayfin looks to back innovative, high-growth healthcare businesses and our investment in GCA, with its leadership position in its key markets and global expansion plans, is consistent with this strategy. We look forward to partnering with GCA’s management team to help achieve the Company’s strategic growth objectives and capitalize on the opportunities for GCA to expand its position in the global aesthetics industry.”

About GC Aesthetics

GC Aesthetics (“GCA”) is an established global medical technology company that develops, manufactures in-house and markets a comprehensive range of proprietary aesthetic products that empower patients to feel safe and confident on their personal journey. Through 30 years of commercial presence, GCA has been dedicated to advancing the science of medical aesthetics and delivering high-quality products under its premium Nagor and Eurosilicone brands, primarily for breast augmentation and breast reconstructive surgery. More than 2.5 million women and men across 70 countries have trusted GCA products, which are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness. The Company’s vertically-integrated strategy enables exceptional clinical, operational and commercial performance, which allows GCA to provide competitively differentiated products to physicians and patients. Through a culture of continuous innovation and dedication to customer-responsiveness, GCA has established itself as a leading provider of medical aesthetics solutions and the partner-of-choice for patients seeking to improve their lives.

About Hayfin Capital Management

Hayfin Capital Management is a leading European-headquartered credit platform that provides lending solutions to corporates and asset management services to institutional clients. Since it was founded in 2009, Hayfin has extended more than €14 billion in loans to over 285 companies. The firm’s total assets under management are valued at c.€10 billion. Hayfin makes public and private investments across the liquidity spectrum through five strategies: direct lending, special opportunities, high-yield credit & syndicated loans, securitized credit, and private equity funds. Hayfin has a diverse international team of over 90 experienced industry professionals. The firm is headquartered in London and has offices in Frankfurt, Madrid, Paris, Luxembourg, New York, and Tel Aviv. Hayfin is authorized and regulated by the Financial Conduct Authority. Further information can be found at hayfin.com. Contacts GC Aesthetics info@gcaesthetics.com

GC Aesthetics Publishes Results of Eight Year Clinical Study

Breast Augmentation is the most popular cosmetic surgery treatment in the world. As the number of augmentations continues to rise, safety has never been more important. With a strong commitment to setting the ‘Gold Standard’ in care, quality and safety for patients and surgeons alike, GC Aesthetics, a global leader in the medical aesthetics space, is conducting a 10-year long-term clinical study into the safety of the implants expertly produced by one of their brands, Eurosilicone.

This is the eight-year interim results update of this ten-year prospective clinical study which reviewed the safety and performance of Eurosilicone’s breast implants at 17 private and university hospitals in France. In total, 526 women were involved in the study, in a total of 995 implants. This study was recently published in the Aesthetic Surgery Journal. Eurosilicone’s results demonstrated a very high safety rate. With a rupture rate of less than 2% and a reoperation rate of 3.6%, the findings were shown to be lower than the nine-year study reported by other breast implant manufacturers. 

Ayse Kocak, CEO of GC Aesthetics comments,

“As a global leader in the breast implant space, GC Aesthetics is committed to defining and upholding the ‘Gold Standard’ when it comes to safety, care and quality. I believe this study is the largest prospective study of breast implants in Europe. We thrive on delivering the best possible products, and the results of the eight-year study further demonstrate our very high safety rate which should give our surgeons and their patients further peace of mind.Whilst we are delighted to see these results, we will continue to use these findings to help further enhance our services and products to ensure we offer the very best to both surgeons and patients.”